Health Condition 1: null- Unstable Vitiligo Health Condition 2: L80- Vitiligo
Conditions
Interventions
Intervention1: Cyclosporine: Group B patients will receive low dose Cyclosporine A 3 mg/kg/day in two divided doses for a total duration of 4 months. Estimation of blood levels of cyclosporine will be
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: Consecutive patients with clinical diagnosis of vitiligo vulgaris and fulfilling the inclusion criteria listed below will be recruited for the study. 1. Patients with actively spreading vitiligo, defined as vitiligo disease activity score (VIDA) score of +4 with or without prior treatment history. 2. Patients of either sex with age 16-60 years.
Exclusion criteria
Exclusion criteria: 1. Segmental Vitiligo. 2. Age 60 years. 3. Leucoderma secondary to other causes. 4. Pregnancy/Lactation. 5. Patients with severe hepatic, renal or other systemic disorder. • Pre existing malignancy. • Immunosuppression. • Hypertension. • Hypocholesterolemia • Aphakia/cataract • History of spontaneous repigmentation of lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To assess the cessation of disease activity by comparing change in VIDA score by two interventions. 2. To assess the difference in extent of repigmentation in each group using Investigatorâ??s Assessment (IA) score and Vitiligo Area Scoring Index (VASI) . Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patientsâ?? assessment (PA) scores at baseline and thereafter at every follow-up visit. 2. Quality of life assessment pre and post treatment. 3. Pattern of spontaneous repigmentation attained, if any, post-treatment. 4. Color matching of repigmented area. 5. Number and extent of disease relapses during post-treatment follow up. 6. Adverse effects. Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactHitaishi Mehta
Post Graduate Institute of Medical Education & Research, Chandigarh
Outcome results
None listed